Arcellx

Medical Science Liaison (Northern California)

Remote

Not SpecifiedCompensation
Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level
Full TimeJob Type
UnknownVisa
Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

Candidates should possess an advanced degree in health sciences (PharmD, M.D., or Ph.D.) with at least 2 years of experience in hematologic malignancy or cell therapy, or a Master's degree with extensive clinical/medical affairs experience. A minimum of 2 years of MSL/Medical Affairs experience in a relevant therapeutic area is required, along with familiarity with healthcare systems and access environments. Strong partnering, influencing, communication, and presentation skills are essential, as is residing within the Northern California territory.

Responsibilities

The Medical Science Liaison will establish and maintain relationships with healthcare professionals in the hematology space, developing and executing territory plans aligned with Medical Affairs strategies. Responsibilities include partnering compliantly with field-based teams, delivering scientific education, collecting insights from thought leaders to inform medical strategies, and representing Arcellx at conferences. The role also involves supporting clinical trial execution and requiring approximately 50-70% domestic travel.

Skills

Cell Therapy
Medical Affairs
Scientific Exchange
Health Care Professionals (HCPs)
Thought Leaders
Medical Education
Insight Collection

Arcellx

Develops immunotherapies for cell therapy

About Arcellx

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary products and partnerships to drive their research and development efforts. The goal is to meet unmet medical needs by providing safe and effective treatment options through their innovative approach to cell therapy.

Gaithersburg, MarylandHeadquarters
2014Year Founded
$194.5MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Unlimited Paid Time Off
Flexible Work Hours
401(k) Company Match
Fully-Paid Parental Leave
Tuition Reimbursement
Relocation Assistance

Risks

Competition from established CAR-T therapies like Abecma and Carvykti could limit market share.
Dependency on Gilead's Kite partnership poses risks if partnership dynamics change.
Phase 3 iMMagine-3 trial delays or failures could impact anito-cel's market timeline.

Differentiation

Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.
The novel D-Domain binder in anito-cel enhances antigen binding and cell killing.
ARC-SparX offers dosable and controllable CAR-T therapy options.

Upsides

Growing investment in personalized medicine aligns with Arcellx's tailored immunotherapies.
Advancements in gene editing like CRISPR enhance precision in engineered cell therapies.
Outpatient CAR-T administration could reduce costs and increase accessibility for Arcellx.

Land your dream remote job 3x faster with AI